$In8bio (INAB.US)$IN8bio Reports No New Deaths or Relapses in Phase 1 Trial of Gamma-Delta T Cell Therapy Benzinga· 1 min ago IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced updated data from the ongoing Phase 1 trial of INB-100, an allogeneic, haploidentical gamma-delta T cell therapy in older patients with hematologic malignancies undergoing haploidentical stem cell transplant (HSCT) with reduced intensity conditioning (RIC) at the 2024 American Society of Hematology (ASH) Annual Meeting, being hosted in San Diego, CA.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more